Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase 3 trial of transarterial embolization plus octreotide LAR in neuroendocrine tumor patients with inoperable liver metastases
2011-006097-76Phase 3Terminated
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Mar 2012
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of octreotide LAR in neuroendocrine tumour (NET) and hepatic metastasis (2 arms), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: progression free survival. Started Mar 2012; status: terminated.
02
Drugs
octreotide LAR
03
Conditions
neuroendocrine tumour (NET)hepatic metastasis
Beyond the preview
Go deeper on 2011-006097-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006097-76.